In vitro and in vivo quality of leukoreduced apheresis platelets stored in a new platelet additive solution

Dumont, Larry J.; Cancelas, José A.; Graminske, Sharon; Friedman, Kenneth D.; Vassallo, Ralph R.; Whitley, Pamela; Rugg, Neeta; Dumont, Deborah F.; Herschel, Louise; Siegal, Alan H.; Szczepiórkowski, Zbigniew M.; Fender, Logan; Razatos, Anna

doi:10.1111/j.1537-2995.2012.03841.x

Cited by 25 publications

(34 citation statements)

References 23 publications

(26 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The studies were done sequentially and not randomized, the apheresis collections were done outside manufacturers' guidelines, and Plasmalyte was used for elutriation of platelets on the Haemonetics system, and it is also not a licensed storage solution. 6 Our data are the best results yet reported in the literature for extended stored platelets and demonstrate that platelet viability is better maintained in vitro than in vivo. Specifically, fresh radiolabeled autologous platelet survivals in the 38 normal subjects in our studies averaged 8.2 6 0.2 days, whereas platelets could be stored in vitro for 13 days with a residual in vivo lifespan of 4.6 6 0.3 for a combined in vitro/in vivo lifespan of almost 18 days, which is fully For personal use only.…”

Section: Discussionsupporting

confidence: 70%

“…18 Murphy 19 suggested that each subject serve as his/her own control by comparing their fresh platelet recoveries and survivals to their poststorage data, and the FDA has adopted this strategy for assessing poststorage platelet quality. 6 We have previously evaluated plasma-stored Haemonetics or Spectra collected platelets for 5 to 8 days, and platelet recoveries and survivals were not significantly different between the 2 systems. 20 With the plasma studies as background, we determined how long platelets could be stored in a PAS.…”

Section: Discussionmentioning

confidence: 97%

“…2,6,26,[39][40][41] de Wildt-Eggen et al provided an excellent review of both in vitro and in vivo results of platelets stored in plasma or PAS. 41 Only 2 prior studies have evaluated platelets stored in PAS beyond 7 days.…”

Section: Discussionmentioning

confidence: 99%

“…4,5 To license platelets based on poststorage radiolabeled autologous platelet viability measurements in normal subjects, the US Food and Drug Administration (FDA) requires that the lower poststorage 95% confidence limits (LCLs) for platelet recoveries are $66% and survivals are $58% of the same subject's radiolabeled fresh recoveries and survivals, respectively. 6 …”

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

Exploratory studies of extended storage of apheresis platelets in a platelet additive solution (PAS)

Slichter

Corson

Jones

et al. 2014

Blood

View full text Add to dashboard Cite

• Extended apheresis platelet storage is dependent on the collection method, storage in a storage solution, and storage bag composition.• The lifespan of the platelet is not intrinsic to the cell, and platelet viability is better maintained in vitro than in vivo.To evaluate the poststorage viability of apheresis platelets stored for up to 18 days in 80% platelet additive solution (PAS)/20% plasma, 117 healthy subjects donated platelets using the Haemonetics MCS1, COBE Spectra (Spectra), or Trima Accel (Trima) systems. Control platelets from the same subjects were compared with their stored test PAS platelets by radiolabeling their stored and control platelets with either 51 chromium or 111 indium. Trima platelets met Food and Drug Administration poststorage platelet viability criteria for only 7 days vs almost 13 days for Haemonetics platelets; ie, platelet recoveries after these storage times averaged 44 6 3% vs 49 6 3% and survivals were 5.4 6 0.3 vs 4.6 6 0.3 days, respectively. The differences in storage duration are likely related to both the collection system and the storage bag. The Spectra and Trima platelets were hyperconcentrated during collection, and PAS was added, whereas the Haemonetics platelets were elutriated with PAS, which may have resulted in less collection injury. When Spectra and Trima platelets were stored in Haemonetics' bags, poststorage viability was significantly improved. Platelet viability is better maintained in vitro than in vivo, allowing substantial increases in platelet storage times. However, implementation will require resolution of potential bacterial overgrowth during storage. (Blood. 2014;123(2):271-280)

show abstract

Section: Discussionsupporting

confidence: 70%

Section: Discussionmentioning

confidence: 97%

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Exploratory studies of extended storage of apheresis platelets in a platelet additive solution (PAS)

Slichter

Corson

Jones

et al. 2014

Blood

View full text Add to dashboard Cite

show abstract

“…A variety of PASs have been developed. Standardized nomenclature labels PAS as PAS‐A to PAS‐G . All these solutions contain varying combinations of citrate, phosphate, acetate, magnesium, potassium, gluconate, and glucose, and the ingredients synergistically act to provide anticoagulation, membrane stabilization, metabolic substrates, buffering activity, apoptosis inhibition, and activation inhibition .…”

Section: Cold Pltsmentioning

confidence: 99%

Future of platelet formulations with improved clotting profile: a short review on human safety and efficacy data

Cancelas

2019

Transfusion

Self Cite

View full text Add to dashboard Cite

BACKGROUND Platelet (PLT) transfusion is a widely used therapy in treating or preventing bleeding and hemorrhage in patients with thrombocytopenia or trauma. Compared to the relative ease of PLT transfusion, current practice for PLT storage at room temperature (RT) for up to 5 to 7 days is inefficient, costly, wasteful, and relatively unsafe. STUDY DESIGN AND METHODS This study was a review of major advances in PLT derivative products with improved hemostatic potential and safety feature. RESULTS Recent progress in understanding the PLT activation and host clearance mechanisms has led to reassessments of current and new storage conditions that employ refrigeration and/or cryopreservation to overcome storage lesions and significantly extend shelf life of PLTs with reduced risk of pathogen contamination. DISCUSSION It is anticipated that future PLT preservation involving cold, frozen, and/or pathogen reduction strategies in proper PLT additive solutions will enable longer term and safer PLT storage.

show abstract

Platelet Products

Callan

Marryott

2016

Manual of Veterinary Transfusion Medicine and Blood Banking

View full text Add to dashboard Cite

In vitro and in vivo quality of leukoreduced apheresis platelets stored in a new platelet additive solution

Cited by 25 publications

References 23 publications

Exploratory studies of extended storage of apheresis platelets in a platelet additive solution (PAS)

Exploratory studies of extended storage of apheresis platelets in a platelet additive solution (PAS)

Future of platelet formulations with improved clotting profile: a short review on human safety and efficacy data

Platelet Products

Contact Info

Product

Resources

About